Stocks News

LAST PRICE
49.7600
TODAY'S CHANGE (%)
Trending Up0.9300 (1.9046%)

Bid / Lots
44.0000/ 1
Ask / Lots
51.0000/ 6
Open / Previous Close
49.0600 / 48.8300
Day Range
Low 48.3700
High 50.1200
52 Week Range
Low 13.0100
High 51.6100
Volume
339,039
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 22, 2024
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Friday Nov 22, 2024 by Dow Jones
  4:05PM ET on Friday Nov 22, 2024 by Dow Jones
  Companies Mentioned: VERA
  
  Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  
  BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 108,000 shares of Class A common stock and restricted stock units (RSUs) for 53,000 shares of Class A common stock to Jason S. Carter, Vera's new Chief Legal Officer, under Vera's 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employee's employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Nov 21, 2024
- DJ Vera Therapeutics Initiated at Overweight by Wells Fargo, from 8:14AM ET on Thursday Nov 21, 2024 by Dow Jones
  8:14AM ET on Thursday Nov 21, 2024 by Dow Jones
  Companies Mentioned: VERA
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/VERA/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 21, 2024 08:14 ET (13:14 GMT)
Nov 18, 2024
- Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer, from 8:00AM ET on Monday Nov 18, 2024 by Dow Jones
  8:00AM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: VERA
  
  Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
  
  BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately.
- Press Release: Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer, from 8:00AM ET on Monday Nov 18, 2024 by Dow Jones
  8:00AM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: VERA
  
  Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
  
  BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately.
Nov 11, 2024
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Monday Nov 11, 2024 by Dow Jones
  4:05PM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: VERA
  
  Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  
  Brisbane, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 4, 2024, the Compensation Committee granted inducement awards consisting of a non-qualified stock option to purchase 54,050 shares of Class A common stock and restricted stock units (RSUs) for 27,025 shares of Class A common stock to seven new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Nov 27, 2024
- DJ Edgewise Therapeutics Is Maintained at Buy by Truist Securities, from 12:10PM ET on Wednesday Nov 27, 2024 by Dow Jones
  12:10PM ET on Wednesday Nov 27, 2024 by Dow Jones
  Companies Mentioned: EWTX
- Truist Raises Price Target on Edgewise Therapeutics to $50 From $33, Keeps Buy Rating, from 7:33AM ET on Wednesday Nov 27, 2024 by MT Newswires
  7:33AM ET on Wednesday Nov 27, 2024 by MT Newswires
  Companies Mentioned: EWTX
Nov 26, 2024
- SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference, from 7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: SWTX
- RBC Initiates Dyne Therapeutics at Outperform, Speculative Risk With $45 Price Target, from 6:22AM ET on Tuesday Nov 26, 2024 by MT Newswires
  6:22AM ET on Tuesday Nov 26, 2024 by MT Newswires
  Companies Mentioned: DYN
- Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, from 6:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  6:00AM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: EWTX
- DJ Dyne Therapeutics Initiated at Outperform by RBC Capital, from 5:12AM ET on Tuesday Nov 26, 2024 by Dow Jones
  5:12AM ET on Tuesday Nov 26, 2024 by Dow Jones
  Companies Mentioned: DYN
Nov 22, 2024
- DJ Edgewise Therapeutics Initiated at Outperform by Evercore ISI Group, from 9:53AM ET on Friday Nov 22, 2024 by Dow Jones
  9:53AM ET on Friday Nov 22, 2024 by Dow Jones
  Companies Mentioned: EWTX
Nov 20, 2024
- DJ SpringWorks Therapeutics Initiated at Outperform by Evercore ISI Group, from 12:10PM ET on Wednesday Nov 20, 2024 by Dow Jones
  12:10PM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: SWTX
Nov 14, 2024
- Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 8:00AM ET on Thursday Nov 14, 2024 by PR Newswire
  8:00AM ET on Thursday Nov 14, 2024 by PR Newswire
  Companies Mentioned: IOVA, ONCY, SWTX, IBRX, SNDX
- Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 8:00AM ET on Thursday Nov 14, 2024 by CNW Group
  8:00AM ET on Thursday Nov 14, 2024 by CNW Group
  Companies Mentioned: IOVA, ONCY, SWTX, IBRX, SNDX

Vera Therapeutics Inc
NASDAQ:VERAUnited States

Search Criteria

Nov 22, 2024

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Friday Nov 22, 2024 by Dow Jones

Nov 21, 2024

DJ Vera Therapeutics Initiated at Overweight by Wells Fargo, from 8:14AM ET on Thursday Nov 21, 2024 by Dow Jones

Nov 18, 2024

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer, from 8:00AM ET on Monday Nov 18, 2024 by Dow Jones

Press Release: Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer, from 8:00AM ET on Monday Nov 18, 2024 by Dow Jones

Nov 11, 2024

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Monday Nov 11, 2024 by Dow Jones

Peers Headlines

Nov 27, 2024

DJ Edgewise Therapeutics Is Maintained at Buy by Truist Securities, from 12:10PM ET on Wednesday Nov 27, 2024 by Dow Jones

Truist Raises Price Target on Edgewise Therapeutics to $50 From $33, Keeps Buy Rating, from 7:33AM ET on Wednesday Nov 27, 2024 by MT Newswires

Nov 26, 2024

SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference, from 7:00AM ET on Tuesday Nov 26, 2024 by Dow Jones

RBC Initiates Dyne Therapeutics at Outperform, Speculative Risk With $45 Price Target, from 6:22AM ET on Tuesday Nov 26, 2024 by MT Newswires

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, from 6:00AM ET on Tuesday Nov 26, 2024 by Dow Jones

DJ Dyne Therapeutics Initiated at Outperform by RBC Capital, from 5:12AM ET on Tuesday Nov 26, 2024 by Dow Jones

Nov 22, 2024

DJ Edgewise Therapeutics Initiated at Outperform by Evercore ISI Group, from 9:53AM ET on Friday Nov 22, 2024 by Dow Jones

Nov 20, 2024

DJ SpringWorks Therapeutics Initiated at Outperform by Evercore ISI Group, from 12:10PM ET on Wednesday Nov 20, 2024 by Dow Jones

Nov 14, 2024

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 8:00AM ET on Thursday Nov 14, 2024 by PR Newswire

Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon, from 8:00AM ET on Thursday Nov 14, 2024 by CNW Group